Research

Cellular

Gastrointestinal adverse events were more frequent with semaglutide (82.8%) compared to placebo (63.2%).

Clinicians should monitor for gastrointestinal side effects when prescribing semaglutide.

StrongSupportsmedium confidence
Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%).
Thomas A. Wadden et al. · JAMA · 2021

Why this rating

Based on a randomized, double-blind, parallel-group, phase 3a study design.

Source

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity

Thomas A. Wadden et al. · JAMA · 2021

DOI 10.1001/jama.2021.1831

rct · n=611Cited 983×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →